Fig. 1 · Structure

Documents & Downloads

Rosuvastatin calcium

Cat. No. A10810 CAS 147098-20-2

HMG-CoA reductase inhibitor

Rosuvastatin (Crestor) is a member of the drug class of statins, used to treat high cholesterol and related conditions, and to prevent cardiovascular disease. Rosuvastatin is a competitive inhibitor of the enzyme HMG-CoA reductase, having a mechanism of action similar to that of other statins.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Rosuvastatin calcium Research Summary

This section summarizes 2 in vitro studies and 2 in vivo studies of Rosuvastatin calcium from 3 published references. In vitro models include HCM; RAW264.7 macrophages (a mouse cell line). In vivo models include apoE-/- mice.

Rosuvastatin calcium In Vitro Studies

In HCM, Rosuvastatin did not reduce cell viability with increasing concentrations after 24 h. In RAW264.7 macrophages treated at 5 µM, statins induced CCR7 gene expression at 1 hour, with maximal induction at 6 hour and the greatest induction observed with Rosuvastatin. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cell Viability in HCM

Cell-based study · HCM [1]

HCM were treated with Rosuvastatin at the tested concentrations for 24 h, with normal culture medium without statins serving as the control. Rosuvastatin did not reduce cell viability with increasing concentrations.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cell viabilityReported result 0, 10, 20, 40, 80 and 160 μM; 24 h: atorvastatin and lovastatin reduced cell viability with increasing concentrations of statins in HCM, C2C12 and HUVEC, while rosuvastatin and pravastatin did not.[1]

Literature-Reported Treatment Conditions

Treatment concentration
0, 10, 20, 40, 80 and 160 μM
Exposure duration
24 h
Vehicle
DMSO
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: Rosuvastatin

The paper names Rosuvastatin without stating the salt or form; not verified as the calcium form supplied as A10810. No dose conversion or lot validation.

Materials and Methods > Cell Culture and Drug Treatments (S5); Materials and Methods > Cell Viability Assay (S8, S9, S10); Results > Ferroptosis Contributes to Atorvastatin-Induced Cell Damage in HCM and C2C12 Cells (S51); FIGURE 1 legend (S116, S117)

cell viability: cell viability; comparator: normal culture medium without addition of any statins — Materials and Methods > Cell Viability Assay (S8); Results > Ferroptosis Contributes to Atorvastatin-Induced Cell Damage in HCM and C2C12 Cells (S51); FIGURE 1 legend (S116)

Rosuvastatin and Macrophage CCR7 Gene Expression

Cell-based study · RAW264.7 macrophages (a mouse cell line) [2]

Mouse macrophages were treated with Rosuvastatin in serum-free media, with DMSO serving as the control. Statins induced CCR7 gene expression, with Rosuvastatin producing the greatest induction.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CCR7 gene expressionReported result CCR7 gene expression was also induced by statins at 1 hour with maximal induction at the 6 hour time point, with the greatest induction by rosuvastatin[2]

Literature-Reported Treatment Conditions

Treatment concentration
5 µM
Exposure duration
1, 3, 6, and 24 hours post treatment
Method
serum-free media
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Rosuvastatin

The paper names Rosuvastatin without stating the salt or form; not verified as the calcium form supplied as A10810. No dose conversion or lot validation.

Results > Statins induce SREBP regulation of CCR7 expression (S35, S37); Materials and Methods > Cell Culture and Treatments (S96, S97, S98)

CCR7 gene expression: CCR7 gene expression; comparator: DMSO — Results > Statins induce SREBP regulation of CCR7 expression (S37)

Rosuvastatin calcium In Vivo Studies

In apoE-/- mice receiving Rosuvastatin alongside a Western-type diet, total cholesterol was 593±31 mg/dL; the compound effect was isolated by comparison with the baseline untreated group. In male mice receiving a high-fat diet and Rosuvastatin, Bacteroidetes relative abundance was 33.7 ± 29.1%. Relative abundances of Bacteroidetes, Firmicutes, and Deferribacteres in the HFD-Ator and HFD-Rosu groups were not significantly different compared with the HFD group. [2,3]

Total Cholesterol in apoE-/- Mice

Animal study · apoE-/- mice [2]

apoE-/- mice received Rosuvastatin milled into food at 2.4 mg/kg mouse per day for 4 weeks alongside a Western-type diet. Total cholesterol was 593±31 mg/dL, with the compound effect isolated by comparison with the baseline untreated group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Total CholesterolTotal Cholesterol 2.4 mg/kg mouse per day, for 4 weeks: 593±31 mg/dL[2]

Conditions shared by the study groups

Route
milled into the food
Treatment course
for 4 weeks
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Rosuvastatin 2.4 mg/kg mouse per daymice not treated with statins, but maintained on the western diet593±31 mg/dL[2]
Rosuvastatin 2.4 mg/kg mouse per day
Model: apoE-/- mice
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Rosuvastatin

The paper names Rosuvastatin without stating the salt or form; not verified as the calcium form supplied as A10810. No dose conversion or lot validation.

Results > Atorvastatin and rosuvastatin decrease total cholesterol without significantly affecting HDL-C in western-diet fed apoE-/- mice (S1, S2, S4); Materials and Methods > Experimental Design & Animals (S63, S64, S65); Table 1 (T1.h1, T1.r1)

Total Cholesterol: Total Cholesterol; comparator: mice not treated with statins, but maintained on the western diet — Materials and Methods > Experimental Design & Animals (S64, S65); Table 1 (T1.h1, T1.r1)

Rosuvastatin 2.4 mg/kg mouse per day · Results > Atorvastatin and rosuvastatin decrease total cholesterol without significantly affecting HDL-C in western-diet fed apoE-/- mice (S1); Materials and Methods > Experimental Design & Animals (S64, S65); Table 1 (T1.h1, T1.r1)

Rosuvastatin and Bacteroidetes Abundance in Mice

Animal study · Male 4-week-old C57BL/6N mice; metabolic disorders such as obesity, hyperglycemia, and hyperlipidemia; n = 6 [3]

Male mice with metabolic disorders received Rosuvastatin daily during high-fat feeding. Relative Bacteroidetes abundance was not significantly different from that in the high-fat-diet control group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Relative abundances of Bacteroidetesrelative abundance of Bacteroidetes 33.7 ± 29.1%[3]

Conditions shared by the study groups

Treatment course
every day during the HFD for the last 16 weeks
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Rosuvastatin 3 mg/kg of body weighta HFD-fed mice group (n = 6)33.7 ± 29.1%; Relative abundances of Bacteroidetes, Firmicutes, and Deferribacteres in the HFD-Ator and HFD-Rosu group were not significantly different compared to the HFD group.[3]
Rosuvastatin 3 mg/kg of body weight
Model: Male 4-week-old C57BL/6N mice; metabolic disorders such as obesity, hyperglycemia, and hyperlipidemia; n = 6
Reported limits: Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: Rosuvastatin

The paper names Rosuvastatin without stating the salt or form; not verified as the calcium form supplied as A10810. No dose conversion or lot validation.

Materials and Methods > Animals and Experimental Protocol (S1, S2, S3, S4); Materials and Methods > Fecal Microbiota Transplantation (FMT) (S33); Results > Effects of Statins and Diet on the Composition of the Gut Microbiota (S56, S60); FIGURE 1 legend (S80)

Relative abundances of Bacteroidetes: Relative abundances of Bacteroidetes; comparator: a HFD-fed mice group (n = 6) — Results > Effects of Statins and Diet on the Composition of the Gut Microbiota (S56, S60)

Rosuvastatin 3 mg/kg of body weight · Materials and Methods > Animals and Experimental Protocol (S3); Results > Effects of Statins and Diet on the Composition of the Gut Microbiota (S56, S60)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 147098-20-2
Applications HMG-CoA reductase inhibitor
Formula C22H28FN3O6S.1/2Ca
Molecular Weight 501.5
Synonyms Crestor
SMILES
CC(C1=NC(=NC(=C1/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C2=CC=C(C=C2)F)N(S(=O)(=O)C)C)C.CC(C1=NC(=NC(=C1/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C2=CC=C(C=C2)F)N(S(=O)(=O)C)C)C.[Ca+2]

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 91 mg/mL (181.79 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
9 mg/mL
Vehicle
4% DMSO+30% PEG 300+dd H2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Rosuvastatin calcium Research References

  1. [1] Zhang Q, Qu H, Chen Y, et al. Atorvastatin Induces Mitochondria-Dependent Ferroptosis via the Modulation of Nrf2-xCT/GPx4 Axis. Front Cell Dev Biol (2022). PMID: 35309902 DOI: 10.3389/fcell.2022.806081 Source material
  2. [2] Feig JE, Shang Y, Rotllan N, et al. Statins promote the regression of atherosclerosis via activation of the CCR7-dependent emigration pathway in macrophages. PLoS One (2011). PMID: 22163030 DOI: 10.1371/journal.pone.0028534 Source material
  3. [3] Kim J, Lee H, An J, et al. Alterations in Gut Microbiota by Statin Therapy and Possible Intermediate Effects on Hyperglycemia and Hyperlipidemia. Front Microbiol (2019). PMID: 31551944 DOI: 10.3389/fmicb.2019.01947 Source material

Added to your cart

View Cart Checkout
Loading...